Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aerocrine raises $50 million in debt, equity

Aerocrine AB (SSE:AERO) raised about $50 million through a $35

Read the full 109 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE